GlassScriptPhysician profile
Duane D Superneau
NPI 1427018274
$516.16
in general payments reported to CMS, 2019-2025
14 companies · $312 in 2025
The $312 reported for 2025 was more than what a typical Clinical Genetics (M.D.) provider received nationally (typical 2025 total: $255).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.70 · 2021: $68.00 · 2022: $5.76 · 2023: $13.59 · 2024: $101 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $426.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zevra Therapeutics INC | $142.97 | 2025 | Olpruva |
| Biomarin Pharmaceutical INC. | $68.00 | 2021 | |
| Abbvie INC. | $58.60 | 2024-2025 | |
| Exact Sciences Corporation | $55.04 | 2024-2025 | Cologuard Collection Kit |
| Genzyme Corporation | $28.35 | 2025 | |
| Mirum Pharmaceuticals, INC. | $24.15 | 2025 | Cholbam |
| Travere Therapeutics, INC. | $21.46 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $19.70 | 2024 | Farxiga |
| Krystal Biotech INC | $19.16 | 2025 | Vyjuvek |
| Phadia US INC. | $18.82 | 2025 | Immunocap |
| Lilly USA, LLC | $17.11 | 2025 | Zepbound, Mounjaro |
| Amgen INC. | $15.45 | 2024 | Prolia, Evenity |
| Csl Behring | $13.76 | 2024 | Hizentra |
| Cook Medical LLC | $13.59 | 2023 | Biodesign |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Duane Superneau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.